Novo Nordisk

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024
Patient, University, Biology, RRP, CSL Behring, Polyp, Principal, MD, Associate, Therapy, DNA, Fireside chats, TB, Stenosis, Tuberculosis, Novo Nordisk, Business administration, Johns Hopkins Hospital, Novartis, Cancer, Disease, Spasmodic dysphonia, Cyst, Johns Hopkins, Bachelor, Infection, Recurrence, MBA, Royal college, CMO, NIH, Shire (pharmaceutical company), Otorhinolaryngology, Human, Medical research, Emergent, Research, Vaccine, Oppenheimer Holdings, Laryngeal cancer, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics

Retrieved on: 
Wednesday, January 17, 2024
Vertex Pharmaceuticals, Patient, Biologics license application, Therapy, Endocrine system, TGF, Heart, LAS, HBA, Spleen, Diagnosis, Anemia, Mouse, Thalassemia, Beta thalassemia, HB, CBC, RBC, Pharmacosmos, Disease, Iron overload, TDT, EU4, FDA, Blas, Prevalence, Liver, Novo Nordisk, PDUFA, Red blood cell, CRISPR Therapeutics, Hemoglobin A, Cell, Iron, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Beta-thalassemia Market Insights report includes a comprehensive understanding of current treatment practices, beta-thalassemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • According to DelveInsight's analysis, the market size for beta-thalassemia across the 7MM is expected to grow with a significant CAGR by 2032.
  • The promising beta-thalassemia therapies in the pipeline include CTX001, EDIT-301, Mitapivat, ACE-536, Panobinostat, Etavopivat tablets, and others.
  • In September 2023, Pharmacosmos has initiated a Phase II trial of SP-420 in patients with transfusion-dependent β-thalassemia.
  • In June 2023, FDA accepted the Biologics License Application (BLAs) of exagamglogene autotemcel (exa-cel) for transfusion-dependent beta thalassemia (TDT).

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics

Retrieved on: 
Wednesday, January 17, 2024
Vertex Pharmaceuticals, Patient, Biologics license application, Therapy, Endocrine system, TGF, Heart, LAS, HBA, Spleen, Diagnosis, Anemia, Mouse, Thalassemia, Beta thalassemia, HB, CBC, RBC, Pharmacosmos, Disease, Iron overload, TDT, EU4, FDA, Blas, Prevalence, Liver, Novo Nordisk, PDUFA, Red blood cell, CRISPR Therapeutics, Hemoglobin A, Cell, Iron, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Beta-thalassemia Market Insights report includes a comprehensive understanding of current treatment practices, beta-thalassemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • According to DelveInsight's analysis, the market size for beta-thalassemia across the 7MM is expected to grow with a significant CAGR by 2032.
  • The promising beta-thalassemia therapies in the pipeline include CTX001, EDIT-301, Mitapivat, ACE-536, Panobinostat, Etavopivat tablets, and others.
  • In September 2023, Pharmacosmos has initiated a Phase II trial of SP-420 in patients with transfusion-dependent β-thalassemia.
  • In June 2023, FDA accepted the Biologics License Application (BLAs) of exagamglogene autotemcel (exa-cel) for transfusion-dependent beta thalassemia (TDT).

Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos

Retrieved on: 
Wednesday, January 17, 2024
Majesty, Electricity, Kilowatt-hour, Novo Nordisk, PPA, Envision Energy, Novartis, Power purchase agreement, Carbon, AstraZeneca, Roche, Professional, Renewable energy

DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced a collaboration with five global leading healthcare companies to accelerate the transition to net zero health systems, delivering around 200 gigawatt-hours (GWh) of green power annually from 2024. This multi-party agreement across healthcare and renewable energy companies brings together for the first time five healthcare leaders - AstraZeneca, Lonza, Novartis, Novo Nordisk and Rocheto advance the industry's sustainable development.

Key Points: 
  • DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced a collaboration with five global leading healthcare companies to accelerate the transition to net zero health systems, delivering around 200 gigawatt-hours (GWh) of green power annually from 2024.
  • This multi-party agreement across healthcare and renewable energy companies brings together for the first time five healthcare leaders - AstraZeneca, Lonza, Novartis, Novo Nordisk and Rocheto advance the industry's sustainable development.
  • The three-year renewable energy supply agreement was announced during the World Economic Forum Annual Meeting in Davos, Switzerland.
  • As a member of the China Council Health Working Group , Envision Energy aims to work with industry leaders to promote the adoption of renewable energy sources and contribute to the green transformation.

Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos

Retrieved on: 
Wednesday, January 17, 2024
Majesty, Electricity, Kilowatt-hour, Novo Nordisk, PPA, Envision Energy, Novartis, Power purchase agreement, Carbon, AstraZeneca, Roche, Professional, Renewable energy

DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced a collaboration with five global leading healthcare companies to accelerate the transition to net zero health systems, delivering around 200 gigawatt-hours (GWh) of green power annually from 2024. This multi-party agreement across healthcare and renewable energy companies brings together for the first time five healthcare leaders - AstraZeneca, Lonza, Novartis, Novo Nordisk and Rocheto advance the industry's sustainable development.

Key Points: 
  • DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced a collaboration with five global leading healthcare companies to accelerate the transition to net zero health systems, delivering around 200 gigawatt-hours (GWh) of green power annually from 2024.
  • This multi-party agreement across healthcare and renewable energy companies brings together for the first time five healthcare leaders - AstraZeneca, Lonza, Novartis, Novo Nordisk and Rocheto advance the industry's sustainable development.
  • The three-year renewable energy supply agreement was announced during the World Economic Forum Annual Meeting in Davos, Switzerland.
  • As a member of the China Council Health Working Group , Envision Energy aims to work with industry leaders to promote the adoption of renewable energy sources and contribute to the green transformation.

The world’s 30 Best Places to Work for 2023 revealed

Retrieved on: 
Saturday, January 13, 2024
Organization, Novo Nordisk, AstraZeneca, Takeda, Workplace

NEW YORK/LONDON/SINGAPORE - Media OutReach Newswire - 9 January 2024 - The Best Places to Work organization announced today the list of the top 30 world Best Places to Work for 2023.

Key Points: 
  • NEW YORK/LONDON/SINGAPORE - Media OutReach Newswire - 9 January 2024 - The Best Places to Work organization announced today the list of the top 30 world Best Places to Work for 2023.
  • AstraZeneca secured the third position among the world top 30 most performing organizations.
  • For the past couple of years, the Best Places to Work program has recognized leading employers across the world, backed by several years of experience in workplace culture assessment, employee engagement and organizational effectiveness.
  • The Top 30 Best Places to Work for 2023:

The World's 30 Best Places to Work for 2023 Revealed

Retrieved on: 
Tuesday, January 9, 2024
Organization, Novo Nordisk, AstraZeneca, Takeda, Workplace

New York, New York and London, United Kingdom and Singapore, Singapore--(Newsfile Corp. - January 9, 2024) - The Best Places to Work organization announced today the list of the top 30 world Best Places to Work for 2023.

Key Points: 
  • New York, New York and London, United Kingdom and Singapore, Singapore--(Newsfile Corp. - January 9, 2024) - The Best Places to Work organization announced today the list of the top 30 world Best Places to Work for 2023.
  • AstraZeneca secured the third position among the world top 30 most performing organizations.
  • For the past couple of years, the Best Places to Work program has recognized leading employers across the world, backed by several years of experience in workplace culture assessment, employee engagement and organizational effectiveness.
  • The Top 30 Best Places to Work for 2023:

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.